Press Release
<< Back
Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718
--The acquisition reduces milestones and royalties associated with ongoing VS-4718 development--
“Controlling ownership of our products is key to value creation,” said
VS-4718 is an oral compound designed to target cancer stem cells through
the potent inhibition of focal adhesion kinase (FAK). Cancer stem cells
are an underlying cause of tumor resistance to chemotherapy, recurrence
and ultimate disease progression. Research by
VS-4718 is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The dose escalation portion of the Phase 1 clinical trial is designed to determine the biologically active dose and the maximum tolerated dose. Additional patients may be enrolled to assess safety, tolerability and to evaluate initial signs of activity.
Under the terms of the Asset Purchase Agreement,
About VS-4718
VS-4718 is an orally available compound designed to target cancer stem
cells through the potent inhibition of focal adhesion kinase (FAK).
Research by
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-4718,
and the Company’s FAK and diagnostic programs generally, the timeline
for clinical development including projected enrollment of trials,
regulatory approval of the Company’s compounds, the expected timing for
the reporting of data from ongoing trials and the structure of the
Company’s planned or pending clinical trials. The words “anticipate,”
“appear,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks that the
preclinical testing of the Company’s compounds and preliminary data from
clinical trials may not be predictive of the results or success of
pending or later clinical trials, that data may not be available when we
expect it to be, that the Company will not be able to enroll a
sufficient number of patients in the expected timeframe, that the
Company will be unable to successfully complete the clinical development
of its compounds, including VS-4718, that the development of the
Company’s compounds will take longer or cost more than planned, and that
the Company’s compounds will not receive regulatory approval or become
commercially successful products. Other risks and uncertainties include
those identified under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended
Source:
Verastem:
Brian Sullivan, 617-252-9314
bsullivan@verastem.com